Ellington Management Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Ellington Management Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-4,900	Closed	-$440K	–	502
2020 Q1	$440K	Buy	+4,900	New	+$481K	0.1%	264
2018 Q4	–	Sell	-2,400	Closed	-$334K	–	664
2018 Q3	$334K	Buy	+2,400	New	+$301K	0.09%	305
2018 Q1	–	Sell	-2,700	Closed	-$323K	–	1084
2017 Q4	$323K	Buy	+2,700	New	+$329K	0.05%	349
2017 Q3	–	Sell	-5,000	Closed	-$608K	–	928
2017 Q2	$608K	Sell	5,000 -200	-4%	-$23.3K	0.09%	190
2017 Q1	$630K	Buy	+5,200	New	+$670K	0.02%	245
2015 Q2	–	Sell	-3,000	Closed	-$520K	–	950
2015 Q1	$520K	Buy	+3,000	New	+$543K	0.11%	271
2013 Q4	–	Sell	-6,200	Closed	-$720K	–	860
2013 Q3	$720K	Buy	+6,200	New	+$680K	0.14%	179

Other funds holding ALXN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ellington Management Group's ALXN Position: Q2 2020 in Review

Ellington Management Group sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 4,900 shares — an estimated $440K sold.

Ellington Management Group first reported a position in ALXN in Q3 2013 and held it in 7 quarters. The position peaked at $720K in Q3 2013. 705 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

Ellington Management Group reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Ellington Management Group sold 4,900 Alexion Pharmaceuticals shares in Q2 2020, an estimated $440K.
Ellington Management Group first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 7 quarters.
Ellington Management Group's Alexion Pharmaceuticals position peaked at $720K in Q3 2013.
705 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.